We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Partek Issues Site-Wide Licenses of Partek® Genomics Suite to the NCI

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Partek Issues Site-Wide Licenses of Partek® Genomics Suite to the NCI"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Partek Incorporated has announced that it has licensed Partek Genomics Suite (Partek GS) to the National Cancer Institute (NCI).

The National Cancer Institute has purchased site-wide licenses of Partek Genomics Suite, making it available to every researcher at the NCI.

"We are extremely pleased that the National Cancer Institute has chosen Partek Genomics Suite," said Tom Downey, President of Partek Incorporated.

"It is exciting to be able to support the NCI in its goal for the diagnosis, prevention, and treatment of cancer."

Partek Genomics Suite is a statistical and visual data analysis software package that is designed to handle thousands of samples and millions of variables in a genomics experiment.

Features include detection and display of alternative splice events, exon-level and copy number alterations, and mapping sites of protein/DNA interaction in ChIP on Chip visualization within the Genome Browser, as well as import and annotation capabilities for two-color arrays.

Additionally, Partek GS is GeneChip-compatible™ and supports Affymetrix gene expression arrays, exon arrays, chromosomal copy number analysis of high-density SNP Arrays, and ChIP on Chip studies for tiling arrays.